AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc AZN paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.AstraZeneca spokesperson told Reuters the company regularly reviews investment priorities and can confirm that the Cambridge expansion is on hold.The news deals a setback to Prime Minister Keir Starmer’s government just days before U.S. President Donald Trump’s state visit. Trump has slammed Britain and Europe for underpaying for drugs, while pharma companies warn that the UK’s ...